Data Indicate Improved Outcomes Using LVADs

The use of left ventricular assist devices (LVADs) is increasing, not only as a bridge to transplant but also as destination therapy. This has generated a growing clinical and academic interest in mechanical circulatory support and the treatment of patients with these devices.

STS/ISHLT Joint Symposium: LVAD Therapy in 2018—Worldwide Perspectives

Tuesday, January 30
1:00 p.m. – 3:00 p.m.
Room 304

In a new session organized by STS and the International Society for Heart & Lung Transplantation, speakers will address these issues for a global audience, including cardiac surgeons, cardiologists, VAD coordinators, and other providers involved in the care of patients with LVADs.

“The goal of the Symposium is to introduce a broad range of practitioners to the most recent clinical trial data and emerging areas of investigation in the field of mechanical circulatory support,” said moderator Gabriel Sayer, MD, of The University of Chicago Medicine.

One topic of particular interest is the optimal approach to LVAD implantation. The progressive miniaturization of these devices has made minimally invasive implantation an attractive option, but challenges exist, and data comparing outcomes with those of conventional implantation are few. Still, the available data indicate improved outcomes with minimally invasive implantation compared with conventional surgery, and many experts believe that minimally invasive implantation should become the preferred approach, unless otherwise indicated.

Another important area of focus is biventricular failure, which is a particular challenge, as little progress has been made in its treatment. In addition, the outcomes associated with biventricular support have been inferior to those associated with left-sided support strategies. New durable biventricular support options are emerging, however, and speakers will describe these options. 

An additional goal of the Symposium is to contrast the American and European experiences with LVAD therapy. Dr. Sayer noted that a highlight will be a presentation by Finn Gustafsson, MD, PhD, of Rigshospitalet in Copenhagen, Denmark, who will discuss the European experience with the HeartMate 3 LVAD. HeartMate 3, which received CE Mark approval in Europe in 2015, has been evaluated in several studies, including the HeartMate 3 CE Mark clinical trial, which demonstrated a 92% survival rate at 6 months. Dr. Gustafsson will discuss the implications of these findings and also will present data from the ELEVATE registry, which was developed to evaluate HeartMate 3 in the post-market approval setting.

 

Top